1. Prevention of host-to-host transmission by SARS-CoV-2 vaccines.
- Author
-
Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, and Iwasaki A
- Subjects
- Antibodies, Viral biosynthesis, Antibodies, Viral immunology, Humans, Immunoglobulin A biosynthesis, Immunoglobulin A immunology, Immunoglobulin G biosynthesis, Immunoglobulin G immunology, Virus Replication immunology, COVID-19 prevention & control, COVID-19 transmission, COVID-19 Vaccines adverse effects, COVID-19 Vaccines immunology
- Abstract
As the number of individuals vaccinated against SARS-CoV-2 rises worldwide, population-level data regarding the vaccines' ability to reduce infection are being generated. Randomised trials have shown that these vaccines dramatically reduce symptomatic COVID-19; however, less is known about their effects on transmission between individuals. The natural course of infection with SARS-CoV-2 involves infection of the respiratory epithelia and replication within the mucosa to sufficient viral titres for transmission via aerosol particles and droplets. Here we discuss the available data on the existing, approved SARS-CoV-2 vaccines' capacity to reduce transmissibility by reducing primary infection, viral replication, capacity for transmission, and symptomaticity. The potential for mucosal-targeted SARS-CoV-2 vaccine strategies to more effectively limit transmission than intramuscular vaccines is considered with regard to known immunological mechanisms. Finally, we enumerate the population-level effects of approved vaccines on transmission through observational studies following clinical trials and vaccine distribution in real-world settings., Competing Interests: Declaration of interests AI is an investigator of the Howard Hughes Medical Institute; serves as a paid consultant to 4BIO; and is a co-founder of RIGImmune. All other authors declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF